Malignant neoplasm of lateral wall of nasopharynx
ICD-10 C11.2 is a billable code used to indicate a diagnosis of malignant neoplasm of lateral wall of nasopharynx.
C11.2 refers to a malignant neoplasm located specifically in the lateral wall of the nasopharynx, which is the upper part of the throat behind the nose. This area is a common site for oropharyngeal and nasopharyngeal cancers, often associated with risk factors such as Epstein-Barr virus (EBV) infection and, in some cases, human papillomavirus (HPV). The lateral wall of the nasopharynx includes structures such as the Eustachian tube orifice and the adenoids, which can be involved in the tumor's growth. Symptoms may include nasal obstruction, ear fullness, and otitis media due to Eustachian tube dysfunction. Diagnosis typically involves imaging studies and biopsy. Treatment often includes radiation therapy, which is a standard approach for localized nasopharyngeal cancers, and may be combined with chemotherapy. The prognosis can vary based on the stage at diagnosis and the tumor's HPV status, with HPV-positive tumors generally having a better prognosis. Accurate coding is essential for appropriate treatment planning and reimbursement.
Detailed pathology reports, imaging studies, and treatment plans must be documented.
Diagnosis and treatment planning for nasopharyngeal cancer, follow-up care post-radiation therapy.
Ensure accurate staging and HPV status documentation for treatment planning.
Comprehensive examination findings, imaging results, and surgical notes if applicable.
Evaluation of nasal obstruction, ear fullness, and biopsy procedures.
Document anatomical details and any surgical interventions performed.
Used in conjunction with C11.2 for treatment planning and delivery.
Radiation treatment plans and delivery notes must be documented.
Oncology must ensure accurate coding of treatment modalities.
HPV status is significant as it can influence treatment decisions and prognosis. HPV-positive tumors generally have a better response to treatment and a more favorable prognosis compared to HPV-negative tumors.
